2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 373

Compared to Non-Users, Current Glucocorticoids Users Have Less Prevalent Fractures at the Same Bone Mass: Results of a Large Cross-Sectional Study
Abstract Number: 2693

Comparing Eight Year Clinical and Radiographic Outcome in Two Cohorts of Patients with Rheumatoid Arthritis
Abstract Number: 311

Comparison Between Intra Articular Ozone and Placebo in the Treatment of Knee Osteoarthritis: A Multicentric, Comparative, Randomized and Double-Blinded Clinical Trial
Abstract Number: 1300

Comparison Between Semiquantitative and Quantitative Methods for the Assessment of Knee Synovitis Using Non-Enhanced and Gadolinium-Enhanced MRI
Abstract Number: 349

Comparison Between the American Recommendations and the Japanese Guidelines for Glucocorticoid-Induced Osteoporosis in Japanese Patients with Rheumatoid Arthritis
Abstract Number: 1548

Comparison of 5 Cardiovascular Risk Calculators in a Hispanic Rheumatoid Arthritis Cohort
Abstract Number: 2636

Comparison of Arterial Health in Patients with Rheumatoid Arthritis to a Population-Based Cohort
Abstract Number: 192

Comparison of Bone Scan with Xiralite (FOI) in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
Abstract Number: 548

Comparison of Dose Escalation and Co-Therapy Intensification Between Patients with Rheumatoid Arthritis Initiating Biologic Treatment with Etanercept, Adalimumab and Infliximab
Abstract Number: 1819

Comparison of Electrocardiographic ST-T Changes and QTc Duration in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 1280

Comparison of Health Service Utilization Costs Between Aboriginal and Non-Aboriginal Patients with Rheumatoid Arthritis Requiring Biologic Therapy
Abstract Number: 1384

Comparison of IgG4-Related and Non-IgG4-Related Retroperitoneal Fibrosis; A 12 Year Retrospective Study
Abstract Number: 2142

Comparison of Interferon-y Release Assay Versus Tuberculin Skin Test in the Golimumab UC and the Golimumab SC Rheumatology (RA, PsA, and AS) Clinical Study Programs
Abstract Number: 1478

Comparison of JIA and RA Patients in the National Data Bank for Rheumatic Diseases
Abstract Number: 2407

Comparison of Knee Osteoarthritis Treatment in the Non-Obese Versus Obese Populations Across Different Medical Specialties

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].